Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: Results from American College of Radiology Imaging Network 6687

Journal of Nuclear Medicine

Volumn 56, Issue 3, 2015, Pages 354-360

  Yu, Evan Y ^a   Duan, Fenghai ^b   Muzi, Mark ^a   Deng, Xuan ^b   Chin, Bennett B ^c   Alumkal, Joshi J ^d   Taplin, Mary Ellen ^e   Taub, Jina M ^a   Herman, Ben ^b   Higano, Celestia S ^a   Doot, Robert K ^f   Hartfeil, Donna ^g   Febbo, Philip G ^h   Mankoff, David A ^f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g AMERICAN COLLEGE OF RADIOLOGY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F fluoride PET; Bone metastases; Dasatinib; Metastatic castration resistant prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; DASATINIB; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; FLUORINE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DRUG RESPONSE; HUMAN; MALE; MULTICENTER STUDY; PET SCANNER; PET-CT SCANNER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; BIOPSY; BONE; BONE TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; IMAGE PROCESSING; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SCINTISCANNING; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BIOPSY; BONE AND BONES; BONE NEOPLASMS; DASATINIB; DISEASE-FREE SURVIVAL; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, ANDROGEN; THIAZOLES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84928114031     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.146936     Document Type: Article

References (26)

1. 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001;45:47-52.
2. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:396-407.
3. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274-292.
4. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623-1629.
5. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633-642.
6. 18F-fluoride positron emission tomography. J Bone Miner Res. 2003;18:2215-2222.
7. 18F-fluoride PET images of breast cancer bone metastases. J Nucl Med. 2010;51:521-527.
8. 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1:4.
9. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185-9189.
10. Fizazi K. The role of Src in prostate cancer. Ann Oncol. 2007;18:1765-1773.
11. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-358.
12. Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003;63:5028-5033.
13. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006;318:161-172.
14. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009;101:263-268.
15. Yu EY, Wilding G, Posadas M, et al. Phase 2 study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421-7428.
16. Yu EY, Massard C, Gross M, et al. Once-daily dasatinib: expansion of a phase 2 study evaluating the safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011;77:1166-1171.
17. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012;118:63-71.
18. Araujo JC, Trudel GC, Saad F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of docetaxel and dasatinib in men with metastatic castration-resistant prostate cancer. Lancet Oncol. 2013;14:1307-1316.
19. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009;27:2022-2029.
20. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
21. Inoue S, Branch CD, Gallick GE, Chada S, Ramesh R. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther. 2005;12:707-715.
22. Lee YC, Huang CF, Murshed M, et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene. 2010;29:3196-3207.
23. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17:4854-4861.
24. Dancey JE, Dodd LE, Ford R, et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer. 2009;45:281-289.
25. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003;34:646-653.
26. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-9216.